

---

## Product Data Sheet

---

Product Name: Margetuximab

Cat. No.: GC68304

### Chemical Properties

Cas. No. 1350624-75-7

Formula M.Wt

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

Margetuximab (MGAH22) is a chimeric anti-**HER2** monoclonal antibody optimized Fc domain, with an **EC<sub>50</sub>** value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer<sup>[1]</sup>.

Margetuximab (MGAH22) enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant<sup>[1]</sup>.

### Cell Proliferation Assay

Cell Line: JIMT-1, MCF-7, ZR-75-1, SKBR-3, HT-29, SW750 and N87<sup>[1]</sup>

Concentration: 0.001-1000 ng/mL

Incubation Time: 6 days

Result: Enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

Margetuximab (2-4 mg/kg; IP 5 or 6 times at weekly) can firstly and significantly reduces the tumor size at day 30 - 37 in mice model<sup>[1]</sup>.

Margetuximab (15-150 mg/kg; IV; 6 weekly) exhibits well tolerated in cynomolgus monkeys, decreases NK cells by an average of 51%, and induces IL-6 release<sup>[1]</sup>.

Margetuximab (50 mg/kg; IV; single dosage) exhibits favorable safety profile<sup>[1]</sup>.

### Pharmacokinetic Parameters of Margetuximab in cynomolgus monkeys<sup>[1]</sup>.

	Male, IV (50 mg/kg)	Female, IV (50 mg/kg)
C <sub>max</sub> (mg/mL)	1.62 ± 0.10	1.70 ± 0.14
AUC <sub>0-∞</sub> (mg.hour/mL)	294.1 ± 53.2	314.2 ± 31.3
T <sub>1/2β</sub> (days)	9.3 ± 1.8	9.7 ± 1.1
Clearance (mL/hour)	0.43 ± 0.07	0.40 ± 0.04
V <sub>SS</sub> (mL)	132 ± 2	127 ± 8

[1]. Nordstrom JL, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---